This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Scancell signs Commercial License Agreement with Genmab

Scancell signs Commercial License Agreement with Genmab

25 Oct 2022

Scancell Holdings plc ("Scancell" or the "Company") Scancell signs Commercial License Agreement with Genmab Genmab granted worldwide license to anti-glycan monoclonal antibody generated via Scancell's proprietary GlyMab® platform, for the development and commercialisation of novel therapeutic products Scancell to receive from Genmab an upfront payment as well as potential milestone payments of up to $208 million for each product... Read more

Nucleome Tx raises £37.5m Series A to decode dark matter of genome & deliver first-in-class drugs

Nucleome Tx raises £37.5m Series A to decode dark matter of genome & deliver first-in-class drugs

19 Oct 2022

Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver first-in-class precision medicines • Financing led by M Ventures alongside other new investors JJDC, Pfizer Ventures and British Patient Capital, and including founding investor Oxford Science Enterprises • Nucleome’s pioneering platform seeks to identify direct genetic linkages to disease-associated genes... Read more

Ochre Bio Raises $30M Series A Financing for the Development of RNA Therapies for Chronic Liver Diseases

Ochre Bio Raises $30M Series A Financing for the Development of RNA Therapies for Chronic Liver Diseases

10 Oct 2022

Ochre Bio Raises $30M Series A Financing for the Development of RNA Therapies for Chronic Liver Diseases Proceeds to support the development of first candidates for IND-enabling studies, as well as expand discovery and RNA chemistry capabilities to address a wider set of serious liver-related diseases. Additional capabilities create one the world’s fastest liver R&D pipelines. In a matter of days, Ochre can identify a novel target,... Read more

Oxford Cancer Biomarkers announces European expansion of chemotherapy toxicity test & independent real-world evidence of patient benefit

Oxford Cancer Biomarkers announces European expansion of chemotherapy toxicity test & independent real-world evidence of patient benefit

26 Sep 2022

ToxNav®, a CE-marked in vitro diagnostics product is now registered in the European database on medical devices (EUDAMED).  Independent study publication highlights patient benefits, cost-savings and opportunity for ToxNav® to address potential health inequalities in current approaches to DPYD testing. OXFORD, UK – 26th September 2022 – Oxford Cancer Biomarkers Ltd (OCB) announces that ToxNav®, its proprietary pharmacogenomics test for... Read more

Scientists Professors Susan Iversen & Anthony Leggett honoured at The Oxford Science Park

Scientists Professors Susan Iversen & Anthony Leggett honoured at The Oxford Science Park

16 Sep 2022

  Scientists Professors Susan Iversen & Anthony Leggett honoured at The Oxford Science Park Names of two new buildings on Plot 16 announced as construction progresses Oxford, UK, September 16 2022 – Two leading scientists, experimental psychologist Professor Susan Iversen CBE FMedSci and Nobel Prize-winning theoretical physicist Professor Sir Anthony Leggett FRS HonFInstP are being honoured today at The Oxford Science Park (TOSP),... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More